Marc Weiner Selected Research

rifapentine (Priftin)

11/2021	Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.
1/2021	Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
1/2021	Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis.
1/2020	Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
1/2020	High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
11/2017	Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
3/2015	Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
2/2015	Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
11/2014	Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.
8/2014	Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Weiner Research Topics

Disease

28	Tuberculosis (Tuberculoses) 11/2021 - 08/2002
11	Pulmonary Tuberculosis 01/2021 - 08/2002
6	Latent Tuberculosis 01/2020 - 12/2011
4	HIV Infections (HIV Infection) 11/2021 - 05/2005
2	Inflammation (Inflammations) 05/2014 - 01/2013
1	Leptospirosis 07/2021
1	Cough 01/2021
1	Cardiac Arrhythmias (Arrythmia) 01/2018
1	Acute-Phase Reaction 01/2013
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 07/2012
1	Body Weight (Weight, Body) 10/2010
1	Bacterial Infections (Bacterial Infection) 02/2005

Drug/Important Bio-Agent (IBA)

18	rifapentine (Priftin)FDA Link 11/2021 - 08/2002
12	Isoniazid (Ftivazide)FDA LinkGeneric 01/2021 - 08/2002
11	Rifampin (Rifampicin)FDA LinkGeneric 01/2021 - 08/2002
10	Pharmaceutical PreparationsIBA 01/2021 - 08/2002
6	Pyrazinamide FDA LinkGeneric 01/2021 - 02/2006
4	Ethambutol (Myambutol)FDA LinkGeneric 01/2021 - 02/2006
4	Moxifloxacin (Avelox)FDA Link 01/2021 - 08/2007
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2011
4	RifamycinsIBA 01/2020 - 05/2005
3	Rifabutin (Ansamycin)FDA Link 02/2006 - 05/2005
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 02/2005
2	AcidsIBA 01/2021 - 05/2016
2	FluoroquinolonesIBA 07/2012 - 02/2005
1	Immunoglobulin M (IgM)IBA 07/2021
1	thiamine triphosphorate (TTP)IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 05/2016
1	Culture MediaIBA 05/2016
1	Nucleic AcidsIBA 05/2016
1	Blood Proteins (Serum Proteins)IBA 05/2014
1	Raltegravir Potassium FDA Link 04/2014
1	Complement System Proteins (Complement)IBA 01/2013
1	Peptide Hydrolases (Proteases)FDA Link 01/2013
1	Proteins (Proteins, Gene)FDA Link 01/2013
1	Nucleotide AptamersIBA 01/2013
1	Ofloxacin (Ofloxacine)FDA LinkGeneric 07/2012
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 11/2005
1	efavirenz (Sustiva)FDA Link 11/2005
1	Ciprofloxacin (Cipro)FDA LinkGeneric 02/2005

Therapy/Procedure

9	Therapeutics 01/2018 - 05/2003
3	Duration of Therapy 01/2021 - 06/2014
1	Drug Therapy (Chemotherapy) 02/2015